AnTolRx

About:

Our lead program addresses significant unmet needs in the field of Type 1 Diabetes

Website: http://antolrx.com/

Top Investors: JDRF (The Juvenile Diabetes Research Foundation), Pfizer Venture Investments, Orion Healthcare Equity Partners

Description:

At AnTolRx they are approaching the treatment of autoimmune diseases differently–through the development of novel nanoparticle-based therapies to promote antigen-specific immune tolerance. Standard therapies broadly suppress the immune system, inducing side effects that may include life threatening infections and tumors. Thus, there is an unmet clinical need for methods of targeted immune-regulation. Their proprietary drug development approach selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases.